Global Irritable Bowel Syndrome Market 2021-2025

Global Irritable Bowel Syndrome Market 2021-2025

Technavio has been monitoring the irritable bowel syndrome market and it is poised to grow by $ 779.89 mn during 2021-2025, progressing at a CAGR of 10.09% during the forecast period. Our report on the irritable bowel syndrome market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by unhealthy lifestyle habits and increasing incidence of gastrointestinal disorders. In addition, unhealthy lifestyle habits is anticipated to boost the growth of the market as well.

The irritable bowel syndrome market analysis includes the type segment and geographic landscape.

Technavio's irritable bowel syndrome market is segmented as below:

By Type

• IBS-D
• IBS-C
• IBS-M

By Geographical Landscape

• North America
• Europe
• Asia
• ROW

This study identifies the increasing awareness of irritable bowel syndromeas one of the prime reasons driving the irritable bowel syndrome market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on irritable bowel syndrome market covers the following areas:

• Irritable bowel syndrome market sizing
• Irritable bowel syndrome market forecast
• Irritable bowel syndrome market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading irritable bowel syndrome market vendors that include AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Novartis AG, Sebela Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. Also, the irritable bowel syndrome market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Companies Mentioned

AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Novartis AG, Sebela Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd.